Antidepressant-Like Activity of Typical Antidepressant Drugs in the Forced Swim Test and Tail Suspension Test in Mice Is Augmented by DMPX, an Adenosine A2A Receptor Antagonist

Akiskal HS, McKinney WT (1973) Depressive disorders: toward a unified hypothesis. Science 182:20–29 Ali-Sisto T, Tolmunen T, Toffol E, Viinamaki H, Mantyselka P, Valkonen-Korhonen M, Honkalampi K, Ruusunen A, Velagapudi V, Lehto SM (2016) Purine metabolism is dysregulated in patients with major depressive disorder. Psychoneuroendocrinology 70:25–32 Armentero MT, Pinna A, Ferré S, Lanciego JL, Müller CE, Franco R (2011) Past, present and future of A(2A) adenosine receptor antagonists in the therapy of Parkinson’s disease. Pharmacol Ther 132:280–299 Berk M, Plein H, Ferreira D, Jersky B (2001) Blunted adenosine A2a receptor function in platelets in patients with major depression. Eur Neuropsychopharmacol 11:183–186 Biagini G, Pich EM, Carani C, Marrama P, Agnati LF (1998) Postnatal maternal separation during the stress hyporesponsive period enhances the adrenocortical response to novelty in adult rats by affecting feedback regulation in the CA1 hippocampal field. Int J Dev Neurosc 16:187–197 Burke MJ, Preskorn SH (2004) Therapeutic drug monitoring of antidepressants. In: Preskorn SH, Feigher JP, Stanga CY, Ross R (eds) Antidepressants: past, present and future. Springer-Verlag, Heidelberg, pp 87–117 Caccia S (1998) Metabolism of the newer antidepressants. An overview of the pharmacological and pharmacokinetic implications. Clin Pharmacokinet 34:281–302 Chau A, Rose JC, Koos BJ (1999) Adenosine modulates corticotropin and cortisol release during hypoxia in fetal sheep. Am J Obstet Gynecol 180:1272–1277 Coelho JE, Alves P, Canas PM, Valadas JS, Shmidt T, Batalha VL, Ferreira DG, Ribeiro JA, Bader M, Cunha RA, do Couto FS, Lopes LV (2014) Overexpression of adenosine A2A receptors in rats: effects on depression, locomotion, and anxiety. Front Psychiatry 5:67 Corset V, Nguyen-Ba-Charvet KT, Forcet C, Moyse E, Chédotal A, Mehlen P (2000) Netrin-1-mediated axon outgrowth and cAMP production requires interaction with adenosine A2b receptor. Nature 407:747–750 Cunha GM, Canas PM, Oliveira CR, Cunha RA (2006) Increased density and synapto-protective effect of adenosine A2A receptors upon sub-chronic restraint stress. Neuroscience 141:1775–1781 Cunha RA (2008) Different cellular sources and different roles of adenosine: A1 receptor-mediated inhibition through astrocytic-driven volume transmission and synapse-restricted A2A receptor-mediated facilitation of plasticity. Neurochem Int 52:65–72 Cunha RA, Ferré S, Vaugeois JM, Chen JF (2008) Potential therapeutic interest of adenosine A2A receptors in psychiatric disorders. Curr Pharm Des 14:1512–1524 Deckert J, Gleiter CH (1989) Adenosinergic psychopharmaceuticals? Trends Pharmacol Sci 10:99–100 Delgado PL (2000) Depression: the case for a monoamine deficiency. J Clin Psychiatry 61(Suppl 6):7–11 Dixon AK, Gubitz AK, Sirinathsinghji DJ, Richardson PJ, Freeman TC (1996) Tissue distribution of adenosine receptor mRNAs in the rat. Br J Pharmacol 118:1461–1468 Duman CH (2010) Models of depression. Vitam Horm 82:1–21 Ebersolt C, Premont J, Prochiantz A, Perez M, Bockaert J (1983) Inhibition of brain adenylate cyclase by A1 adenosine receptors: pharmacological characteristics and locations. Brain Res 267:123–129 El Yacoubi M, Costentin J, Vaugeois JM (2003) Adenosine A2A receptors and depression. Neurology 61:S82–S87 El Yacoubi M, Ledent C, Parmentier M, Bertorelli R, Ongini E, Costentin J, Vaugeois JM (2001) Adenosine A2A receptor antagonists are potential antidepressants: evidence based on pharmacology and A2A receptor knockout mice. Br J Pharmacol 134:68–77 Ferré S, Fredholm BB, Morelli M, Popoli P, Fuxe K (1997) Adenosine-dopamine receptor-receptor interactions as an integrative mechanism in the basal ganglia. Trends Neurosci 20:482–487 Ferré S, Fuxe K (1992) Dopamine denervation leads to an increase in the intramembrane interaction between adenosine A2 and dopamine D2 receptors in the neostriatum. Brain Res 594:124–130 Ferré S, Fuxe K, von Euler G, Johansson B, Fredholm BB (1992) Adenosine-dopamine interactions in the brain. Neuroscience 51:501–512 Ferré S, O'Connor WT, Svenningsson P, Bjorklund L, Lindberg J, Tinner B, Stromberg I, Goldstein M, Ogren SO, Ungerstedt U, Fredholm BB, Fuxe K (1996a) Dopamine D1 receptor-mediated facilitation of GABAergic neurotransmission in the rat strioentopenduncular pathway and its modulation by adenosine A1 receptor-mediated mechanisms. Eur J Neurosci 8:1545–1553 Ferré S, Popoli P, Tinner-Staines B, Fuxe K (1996b) Adenosine A1 receptor-dopamine D1 receptor interaction in the rat limbic system: modulation of dopamine D1 receptor antagonist binding sites. Neurosci Lett 19:109–112 Fink JS, Weaver DR, Rivkees SA, Peterfreund RA, Pollack AE, Adler EM, Reppert SM (1992) Molecular cloning of the rat A2 adenosine receptor: selective co-expression with D2 dopamine receptors in rat striatum. Brain Res Mol Brain Res 14:186–195 Fredholm BB (2010) Adenosine receptors as drug targets. Exp Cell Res 316:1284–1288 Fredholm BB, Arslan G, Halldner L, Kull B, Schulte G, Wasserman W (2000) Structure and function of adenosine receptors and their genes. Naunyn Schmiedeberg's Arch Pharmacol 362:364–374 Fredholm BB, Battig K, Holmen J, Nehlig A, Zvartau EE (1999) Actions of caffeine in the brain with special reference to factors that contribute to its widespread use. Pharmacol Rev 51:83–133 Fredholm BB, Chen JF, Cunha RA, Svenningsson P, Vaugeois JM (2005a) Adenosine and brain function. Int Rev Neurobiol 63:191–270 Fredholm BB, Chen JF, Masino SA, Vaugeois JM (2005b) Actions of adenosine at its receptors in the CNS: insights from knockouts and drugs. Annu Rev Pharmacol Toxicol 45:385–412 Fredholm BB, IJzerman AP, Jacobson KA, Klotz KN, Linden J (2001) International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol Rev 53:527–552 Gillman PK (2007) Tricyclic antidepressant pharmacology and therapeutic drug interactions updated. Br J Pharmacol 151:737–748 Gomes CV, Kaster MP, Tome AR, Agostinho PM, Cunha RA (2011) Adenosine receptors and brain diseases: neuroprotection and neurodegeneration. Biochim Biophys Acta 1808:1380–1399 Guengerich FP (2008) Cytochrome p450 and chemical toxicology. Chem Res Toxicol 21:70–83 Hashimoto K (2011) The role of glutamate on the action of antidepressants. Prog Neuro-Psychopharmacol Biol Psychiatry 35:1558–1568 Heurteaux C, Lauritzen I, Widmann C, Lazdunski M (1995) Essential role of adenosine, adenosine A1 receptors, and ATP-sensitive K+ channels in cerebral ischemic preconditioning. Proc Natl Acad Sci U S A 92:4666–4670 Hunter AM, Balleine BW, Minor TR (2003) Helplessness and escape performance: glutamate-adenosine interactions in the frontal cortex. Behav Neurosci 117:123–135 Jenner P (2003) A2A antagonists as novel non-dopaminergic therapy for motor dysfunction in PD. Neurology 61:S32–S38 Jenner P, Mori A, Hauser R, Morelli M, Fredholm BB, Chen JF (2009) Adenosine, adenosine A2A antagonists, and Parkinson’s disease. Parkinsonism Relat Disord 15:406–413 Kale PP, Addepalli V (2014) Augmentation of antidepressant effects of duloxetine and bupropion by caffeine in mice. Pharmacol Biochem Behav 124:238–244 Kaster MP, Machado NJ, Silva HB, Nunes A, Ardais AP, Santana M, Baqi Y, Muller CE, Rodrigues AL, Porciuncula LO, Chen JF, Tome AR, Agostinho P, Canas PM, Cunha RA (2015) Caffeine acts through neuronal adenosine A2A receptors to prevent mood and memory dysfunction triggered by chronic stress. Proc Natl Acad Sci U S A 112:7833–7838 Kulkarni SK, Mehta AK (1985) Purine nucleoside-mediated immobility in mice: reversal by antidepressants. Psychopharmacology 85:460–463 Lara DR (2010) Caffeine, mental health, and psychiatric disorders. J Alzheimers Dis 20(Suppl 1):S239–S248 Linden J (1991) Structure and function of A1 adenosine receptors. FASEB J 5:2668–2676 Linden J, Tucker AL, Lynch KR (1991) Molecular cloning of adenosine A1 and A2 receptors. Trends Pharmacol Sci 12:326–328 Mahan LC, McVittie LD, Smyk-Randall EM, Nakata H, Monsma FJ, Gerfen CR, Sibley DR (1991) Cloning and expression of an A1 adenosine receptor from rat brain. Mol Pharmacol 40:1–7 Minor TR, Winslow JL, Chang WC (1994) Stress and adenosine: II. Adenosine analogs mimic the effect of inescapable shock on shuttle-escape performance in rats. Behav Neurosci 108:265–276 Murray CJ, Lopez AD (1997) Alternative projections of mortality and disability by cause 1990–2020: Global Burden of Disease Study. Lancet 349:1498–1504 Nelson DR, Zeldin DC, Hoffman SM, Maltais LJ, Wain HM, Nebert DW (2004) Comparison of cytochrome P450 (CYP) genes from the mouse and human genomes, including nomenclature recommendations for genes, pseudogenes and alternative-splice variants. Pharmacogenetics 14:1–18 Okada M, Nutt DJ, Murakami T, Zhu G, Kamata A, Kawata Y, Kaneko S (2001) Adenosine receptor subtypes modulate two major functional pathways for hippocampal serotonin release. J Neurosci 21:628–640 Olah ME, Stiles GL (1992) Adenosine receptors. Annu Rev Physiol 54:211–225 Olah ME, Stiles GL (2000) The role of receptor structure in determining adenosine receptor activity. Pharmacol Ther 85:55–75 Ortiz R, Ulrich H, Zarate CA Jr, Machado-Vieira R (2015) Purinergic system dysfunction in mood disorders: a key target for developing improved therapeutics. Prog Neuro-Psychopharmacol Biol Psychiatry 57:117–131 Pariante CM, Lightman SL (2008) The HPA axis in major depression: classical theories and new developments. Trends Neurosci 31:464–468 Pariante CM, Miller AH (2001) Glucocorticoid receptors in major depression: relevance to pathophysiology and treatment. Biol Psychiatry 49:391–404 Perez-Lloret S, Merello M (2014) Two new adenosine receptor antagonists for the treatment of Parkinson’s disease: istradefylline versus tozadenant. Expert Opin Pharmacother 15:1097–1107 Poleszak E (2007) Modulation of antidepressant-like activity of magnesium by serotonergic system. J Neural Transm (Vienna) 114:1129–1134 Poleszak E, Stasiuk W, Szopa A, Wyska E, Serefko A, Oniszczuk A, Wośko S, Świąder K, Wlaź P (2016a) Traxoprodil, a selective antagonist of the NR2B subunit of the NMDA receptor, potentiates the antidepressant-like effects of certain antidepressant drugs in the forced swim test in mice. Metab Brain Dis 31:803–814 Poleszak E, Szopa A, Wyska E, Kukuła-Koch W, Serefko A, Wośko S, Bogatko K, Wróbel A, Wlaź P (2016b) Caffeine augments the antidepressant-like activity of mianserin and agomelatine in forced swim and tail suspension tests in mice. Pharmacol Rep 68:56–61 Poleszak E, Szopa A, Wyska E, Wośko S, Serefko A, Wlaź A, Pieróg M, Wróbel A, Wlaź P (2015) The influence of caffeine on the activity of moclobemide, venlafaxine, bupropion and milnacipran in the forced swim test in mice. Life Sci 136:13–18 Poleszak E, Wlaź P, Szewczyk B, Kędzierska E, Wyska E, Librowski T, Szymura-Oleksiak J, Fidecka S, Pilc A, Nowak G (2005) Enhancement of antidepressant-like activity by joint administration of imipramine and magnesium in the forced swim test: behavioral and pharmacokinetic studies in mice. Pharmacol Biochem Behav 81:524–529 Poleszak E, Wlaź P, Szewczyk B, Wlaź A, Kasperek R, Wróbel A, Nowak G (2011) A complex interaction between glycine/NMDA receptors and serotonergic/noradrenergic antidepressants in the forced swim test in mice. J Neural Transm 118:1535–1546 Poleszak E, Wośko S, Serefko A, Szopa A, Wlaź A, Szewczyk B, Nowak G, Wlaź P (2013) Effects of ifenprodil on the antidepressant-like activity of NMDA ligands in the forced swim test in mice. Prog Neuro-Psychopharmacol Biol Psychiatry 46:29–35 Porsolt RD, Bertin A, Jalfre M (1977) Behavioral despair in mice: a primary screening test for antidepressants. Arch Int Pharmacodyn Ther 229:327–336 Reul JM, Labeur MS, Grigoriadis DE, De Souza EB, Holsboer F (1994) Hypothalamic-pituitary-adrenocortical axis changes in the rat after long-term treatment with the reversible monoamine oxidase-A inhibitor moclobemide. Neuroendocrinology 60:509–519 Reul JM, Stec I, Soder M, Holsboer F (1993) Chronic treatment of rats with the antidepressant amitriptyline attenuates the activity of the hypothalamic-pituitary-adrenocortical system. Endocrinology 133:312–320 Rosin DL, Robeva A, Woodard RL, Guyenet PG, Linden J (1998) Immunohistochemical localization of adenosine A2A receptors in the rat central nervous system. J Comp Neurol 401:163–186 Ruby CL, Adams CA, Mrowicka M, Choi DS (2011) Adenosine signaling in anxiety. In: Kalinin V (ed) Anxiety disorders. InTech, New Jersey, pp 52–68 Scaccianoce S, Navarra D, Di SA, Angelucci L, Endroczi E (1989) Adenosine and pituitary-adrenocortical axis activity in the rat. Neuroendocrinology 50:464–468 Schiffmann SN, Jacobs O, Vanderhaeghen JJ (1991a) Striatal restricted adenosine A2 receptor (RDC8) is expressed by enkephalin but not by substance P neurons: an in situ hybridization histochemistry study. J Neurochem 57:1062–1067 Schiffmann SN, Libert F, Vassart G, Vanderhaeghen JJ (1991b) Distribution of adenosine A2 receptor mRNA in the human brain. Neurosci Lett 130:177–181 Sebastião AM, Ribeiro JA (1996) Adenosine A2 receptor-mediated excitatory actions on the nervous system. Prog Neurobiol 48:167–189 Sebastião AM, Ribeiro JA (2009) Adenosine receptors and the central nervous system. Handb Exp Pharmacol 193:471–534 Steru L, Chermat R, Thierry B, Simon P (1985) The tail suspension test: a new method for screening antidepressants in mice. Psychopharmacology 85:367–370 Svenningsson P, Hall H, Sedvall G, Fredholm BB (1997a) Distribution of adenosine receptors in the postmortem human brain: an extended autoradiographic study. Synapse 27:322–335 Svenningsson P, Le Moine C, Kull B, Sunahara R, Bloch B, Fredholm BB (1997b) Cellular expression of adenosine A2A receptor messenger RNA in the rat central nervous system with special reference to dopamine innervated areas. Neuroscience 80:1171–1185 Szewczyk B, Brański P, Wierońska JM, Pałucha A, Pilc A, Nowak G (2002) Interaction of zinc with antidepressants in the forced swimming test in mice. Pol J Pharmacol 54:681–685 Szewczyk B, Poleszak E, Wlaź P, Wróbel A, Blicharska E, Cichy A, Dybała M, Siwek A, Pomierny-Chamioło L, Piotrowska A, Brański P, Pilc A, Nowak G (2009) The involvement of serotonergic system in the antidepressant effect of zinc in the forced swim test. Prog Neuro-Psychopharmacol Biol Psychiatry 33:323–329 Szopa A, Doboszewska U, Herbet M, Wośko S, Wyska E, Świąder K, Serefko A, Korga A, Wlaź A, Wróbel A, Ostrowska M, Terlecka J, Kanadys A, Poleszak E, Dudka J, Wlaź P (2017) Chronic treatment with caffeine and its withdrawal modify the antidepressant-like activity of ve serotonin reuptake inhibitors in the forced swim and tail suspension tests in mice. Effects on Comt, Slc6a15 and Adora1 gene expression. Toxicol Appl Pharmacol 337:95–103 Szopa A, Poleszak E, Wyska E, Serefko A, Wośko S, Wlaź A, Pieróg M, Wróbel A, Wlaź P (2016) Caffeine enhances the antidepressant-like activity of common antidepressant drugs in the forced swim test in mice. Naunyn Schmiedebergs Arch Pharmacol 389:211–221 Tondo L, Isacsson G, Baldessarini R (2003) Suicidal behaviour in bipolar disorder: risk and prevention. CNS Drugs 17:491–511 Vetulani J (2013) Early maternal separation: a rodent model of depression and a prevailing human condition. Pharmacol Rep 65:1451–1461 Yamada K, Kobayashi M, Kanda T (2014) Involvement of adenosine A2A receptors in depression and anxiety. Int Rev Neurobiol 119:373–393 Yamada K, Kobayashi M, Mori A, Jenner P, Kanda T (2013) Antidepressant-like activity of the adenosine A(2A) receptor antagonist, istradefylline (KW-6002), in the forced swim test and the tail suspension test in rodents. Pharmacol Biochem Behav 114-115:23–30 Yamato T, Yamasaki S, Misumi Y, Kino M, Obata T, Aomine M (2002) Modulation of the stress response by coffee: an in vivo microdialysis study of hippocampal serotonin and dopamine levels in rat. Neurosci Lett 332:87–90 Yang M, Soohoo D, Soelaiman S, Kalla R, Zablocki J, Chu N, Leung K, Yao L, Diamond I, Belardinelli L, Shryock JC (2007) Characterization of the potency, selectivity, and pharmacokinetic profile for six adenosine A2A receptor antagonists. Naunyn Schmiedeberg's Arch Pharmacol 375:133–144 Zanger UM, Turpeinen M, Klein K, Schwab M (2008) Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation. Anal Bioanal Chem 392:1093–1108